Research programme: amino acyl-tRNA synthetases - aTyr Pharma

Drug Profile

Research programme: amino acyl-tRNA synthetases - aTyr Pharma

Alternative Names: Amino acyl-tRNA synthetase splice variants - aTyr Pharma; AspRSlN1 (C76S); DRS1-154 (C76S); Homeokine; Phe-tRNA Synthetase; Physiocrines - aTyr Pharma; Resected amino acyl-tRNA synthetase - aTyr Pharma; Resected aspartyl-tRNA synthetase - aTyr Pharma; Tmax; Truncated aspartyl-tRNA synthetase - aTyr Pharma; Tyrosyl-tRNA Synthetase

Latest Information Update: 22 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator aTyr Pharma
  • Class Amino acyl-tRNA synthetases; Angiogenic proteins; Anti-inflammatories; Biological proteins; Proteins
  • Mechanism of Action Angiogenesis inducing agents; Cytokine receptor modulators; G protein-coupled receptor modulators; Histidine-tRNA ligase modulators; Toll-like receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Thrombocytopenia
  • Research Charcot-Marie-Tooth disease
  • No development reported Immunological disorders; Inflammation; Metabolic disorders

Most Recent Events

  • 14 Aug 2018 Preclinical development is ongoing in Thrombocytopenia
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Immunological-disorders in USA
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammation in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top